Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±â ½ÃÀå º¸°í¼ : Á¦Ç° À¯Çü, ¸ð´Þ¸®Æ¼, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2025-2033³â)
Blood Gas and Electrolyte Analyzer Market Report by Product Type (Analyzers, Consumables), Modality (Benchtop, Portable), End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others), and Region 2025-2033
»óǰÄÚµå
:
1722750
¸®¼Ä¡»ç
:
IMARC Group
¹ßÇàÀÏ
:
2025³â 05¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 143 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼¼°è Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±â ½ÃÀå ±Ô¸ð´Â 2024³â 22¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2033³â±îÁö 37¾ï ´Þ·¯¿¡ ´ÞÇϰí, 2025-2033³â 5.37%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ½ÉÇ÷°ü ÇÕº´Áõ, ¾Ï, ´ç´¢º´ µî ´Ù¾çÇÑ ¸¸¼ºÁúȯ Áõ°¡, ±â±â ¼ÒÇüÈ ¹× Á¤È®µµ Çâ»óÀ» À§ÇÑ Ã·´Ü ±â¼ú ÅëÇÕ Áõ°¡, ÇöÀåÁø´Ü(POC) °Ë»ç ¼ºñ½º äÅà Áõ°¡ µîÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ²ÅÈü´Ï´Ù.
Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±â´Â ÀüÇ÷ °Ëü ³»ÀÇ Ç÷¾×°¡½º(ÀÌ»êÈź¼Ò¿Í »ê¼ÒÀÇ ºÐ¾Ð), pH, ÀüÇØÁú, ´ë»ç»ê¹° µî ´Ù¾çÇÑ ÆÄ¶ó¹ÌÅ͸¦ ÃøÁ¤ÇÏ´Â µ¥ »ç¿ëµÇ´Â ÀÇ·á±â±â¸¦ ¸»ÇÕ´Ï´Ù. ´ë»ç ÀÌ»ó °¨Áö ¹× ½ÅÀå ±â´É, ½ÉÀå ±â´É ÃøÁ¤¿¡ ³Î¸® ÀÌ¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ç÷¾× ³» ºñÁ¤»óÀûÀÎ ÀüÇØÁú ¼öÁØ, »ê¼Ò ¹× ÀÌ»êÈź¼Ò ±³È¯ ¼öÁØ, ȯÀÚÀÇ »ê¿°±â ÆòÇüÀ» ÆÇ´ÜÇÏ´Â µ¥µµ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ´ç´¢º´, Ç÷°ü ³» ÃâÇ÷, ¾à¹° ¼·Ãë µîÀ» ÆÄ¾ÇÇÏ´Â µ¥µµ µµ¿òÀÌ µË´Ï´Ù. ÃÖ±Ù ¸î ³â µ¿¾È Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±â´Â »ç¿ë ÆíÀǼº, ºñ¿ë È¿À²¼º, Á¤È®¼º ¹× ºü¸¥ °á°ú·Î ÀÎÇØ ÀÓ»ó Áø´Ü ½ÇÇè½Ç ¹× ÁßȯÀڽǿ¡¼ Å« Àα⸦ ¾ò°í ÀÖ½À´Ï´Ù.
Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±â ½ÃÀå µ¿Çâ :
Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±â´Â ÀÛ¾÷ ÇÁ·Î¼¼½º¸¦ °£¼ÒÈÇϰí, ¿À·ù¸¦ ÃÖ¼ÒÈÇϸç, ÃÖ¼ÒÇÑÀÇ À¯Áöº¸¼ö·Î Á¤È®ÇÑ °á°ú¸¦ ½Å¼ÓÇÏ°Ô Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ±× °á°ú, ÁßȯÀÚ½Ç(ICU), ¼ö¼ú½Ç, ÀÀ±Þ½ÇÀÇ È¯ÀÚ ¼ö Áõ°¡°¡ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î ´ç´¢º´, ½ÉÇ÷°ü Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀÇ È®»ê°ú ÀÌ·¯ÇÑ Áúȯ¿¡ °É¸®±â ½¬¿î ³ë·É Àα¸ Áõ°¡´Â Á¦Ç° ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °í󸮷®, ÅëÇÕÈ, ÀÚµ¿È ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿äµµ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±â¿Í °Ë»ç Á¤º¸ ½Ã½ºÅÛ ¹× ÀüÀÚ ÀÇ·á ±â·Ï°úÀÇ ÅëÇÕÀÌ ÁøÇàµÇ¾î ¿öÅ©Ç÷ο츦 °£¼ÒÈÇϰí ȯÀÚÀÇ °Ç° »óŸ¦ È¿°úÀûÀ¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ°Ô µÈ °ÍÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸î¸î ÁÖ¿ä ±â¾÷µéÀº »ç¿ëÇϱ⠽±°í Ãë±ÞÀÌ °£ÆíÇϸç À¯Áöº¸¼ö°¡ ÇÊ¿ä ¾ø´Â ÈÞ´ë¿ë Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±â °³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ±âŸ ¿äÀÎÀ¸·Î´Â ÇöÀå °Ë»ç(POCT)¿¡ ´ëÇÑ ¼±È£µµ º¯È, ÇコÄÉ¾î »ê¾÷ÀÇ ¹ßÀü, ±â¼ú ¹ßÀü, Á¦Ç° Çõ½Å, ±¤¹üÀ§ÇÑ Á¶»ç °³¹ß(R&D) Ȱµ¿ µîÀÌ ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ¿äÀε鵵 ½ÃÀå Àü¸ÁÀ» ±àÁ¤ÀûÀ¸·Î ¸¸µé°í ÀÖ½À´Ï´Ù.
º» º¸°í¼¿¡¼ ´Ù·é ÁÖ¿ä Áú¹®
- Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±â ½ÃÀå ±Ô¸ð´Â?
- 2025-2033³â ¼¼°è Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±â ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
- Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±â ¼¼°è ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀº?
- Äڷγª19°¡ Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±â ¼¼°è ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
- Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±â ¼¼°è ½ÃÀå¿¡¼ÀÇ Á¦Ç° À¯Çüº° ºÐ·ù´Â?
- Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±â ¼¼°è ½ÃÀå ³» Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±âÀÇ ¾ç½Äº° ºÐ·ù´Â?
- Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±â ¼¼°è ½ÃÀåÀ» ÃÖÁ¾ »ç¿ëÀÚº°·Î ºÐ·ùÇϸé?
- Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±â ¼¼°è ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
- Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±â ¼¼°è ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº?
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý
- Á¶»ç ¸ñÀû
- ÀÌÇØ°ü°èÀÚ
- µ¥ÀÌÅÍ ¼Ò½º
- ½ÃÀå ÃßÁ¤
- Á¶»ç ¹æ¹ý
Á¦3Àå ÁÖ¿ä ¿ä¾à
Á¦4Àå ¼·Ð
Á¦5Àå ¼¼°èÀÇ Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±â ½ÃÀå
- ½ÃÀå °³¿ä
- ½ÃÀå ½ÇÀû
- COVID-19ÀÇ ¿µÇâ
- ½ÃÀå ¿¹Ãø
Á¦6Àå ½ÃÀå ºÐ¼® : Á¦Ç° À¯Çüº°
Á¦7Àå ½ÃÀå ºÐ¼® : ¸ð´Þ¸®Æ¼º°
Á¦8Àå ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°
- º´¿ø
- Ŭ¸®´Ð
- ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
- ±âŸ
Á¦9Àå ½ÃÀå ºÐ¼® : Áö¿ªº°
- ºÏ¹Ì
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- ÀϺ»
- Àεµ
- Çѱ¹
- È£ÁÖ
- Àεµ³×½Ã¾Æ
- ±âŸ
- À¯·´
- µ¶ÀÏ
- ÇÁ¶û½º
- ¿µ±¹
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ·¯½Ã¾Æ
- ±âŸ
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦10Àå SWOT ºÐ¼®
Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®
Á¦12Àå PorterÀÇ Five Forces ºÐ¼®
- °³¿ä
- ¹ÙÀ̾îÀÇ ±³¼··Â
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- °æÀï Á¤µµ
- ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
Á¦13Àå °¡°Ý ºÐ¼®
Á¦14Àå °æÀï ±¸µµ
- ½ÃÀå ±¸Á¶
- ÁÖ¿ä ±â¾÷
- ÁÖ¿ä ±â¾÷ °³¿ä
- Abbott Laboratories Inc.
- Dalko Diagnostics
- Erba Group(Transasia Bio-Medicals Ltd.)
- Medica Corporation
- Nova Biomedical Corporation
- OPTI Medical Systems Inc.(IDEXX Laboratories)
- Radiometer Medical ApS(Danaher Corporation)
- Roche Holding AG
- Siemens AG
- WerfenLife S.A.
LSH
¿µ¹® ¸ñÂ÷
The global blood gas and electrolyte analyzer market size reached USD 2.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.7 Billion by 2033, exhibiting a growth rate (CAGR) of 5.37% during 2025-2033. The growing occurrence of various chronic illnesses like cardiovascular complications, cancer, and diabetes, increasing integration of advanced technologies to decrease the size of devices and enhance accuracy, and rising adoption of point-of-care (POC) testing services are some of the factors impelling the growth of the market.
Blood gas and electrolyte analyzers refer to medical devices used to measure various parameters, including blood gas (partial pressure of carbon dioxide and oxygen), pH, electrolytes, and metabolites, in a whole blood sample. They are widely utilized for the detection of metabolic imbalances and the measurement of renal and cardiac functions. They also help determine abnormal electrolyte levels in the blood, levels of oxygen or carbon dioxide exchange, and the acid-base balance of the patient. Moreover, they assist in identifying diabetes, blood vessel hemorrhage, and drug consumption. In recent years, blood gas and electrolyte analyzers have gained immense popularity across clinical diagnostic labs and critical care units due to their ease of use, cost-effectiveness, accuracy, and fast results.
Blood Gas and Electrolyte Analyzer Market Trends:
Blood gas and electrolyte analyzers can streamline work processes, minimize errors, require minimum maintenance, and provide accurate results quickly. As a result, the increasing number of patients in intensive care units (ICUs), operating rooms, and emergency departments represent the primary factor driving the market growth. Besides this, the widespread prevalence of chronic diseases, such as diabetes and cardiovascular disorders, and the growing geriatric population that is more susceptible to developing these medical ailments are augmenting the product demand. Additionally, there has been a significant increase in the demand for high throughput, integrated, and automated systems. Along with this, the rising integration of blood gas and electrolyte analyzers with laboratory information systems and electronic medical records to streamline the workflow and enable effective monitoring of patient health is catalyzing the market growth. Furthermore, several leading players are making heavy investments for the development of portable blood gas and electrolyte analyzers with easy-to-use and handle features and minimum maintenance requirements. Other factors, including the shifting preferences toward point-of-care testing (POCT), developments in the healthcare industry, technological advancements, product innovations, and extensive research and development (R&D) activities, are also creating a favorable market outlook.
Key Market Segmentation:
Breakup by Product Type:
Breakup by Modality:
Breakup by End User:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories Inc., Dalko Diagnostics, Erba Group (Transasia Bio-Medicals Ltd.), Medica Corporation, Nova Biomedical Corporation, OPTI Medical Systems Inc. (IDEXX Laboratories), Radiometer Medical ApS (Danaher Corporation), Roche Holding AG, Siemens AG, and WerfenLife S.A.
Key Questions Answered in This Report
- 1.How big is the blood gas and electrolyte analyzer market?
- 2.What is the expected growth rate of the global blood gas and electrolyte analyzer market during 2025-2033?
- 3.What are the key factors driving the global blood gas and electrolyte analyzer market?
- 4.What has been the impact of COVID-19 on the global blood gas and electrolyte analyzer market?
- 5.What is the breakup of the global blood gas and electrolyte analyzer market based on the product type?
- 6.What is the breakup of the global blood gas and electrolyte analyzer market based on the modality?
- 7.What is the breakup of the global blood gas and electrolyte analyzer market based on the end user?
- 8.What are the key regions in the global blood gas and electrolyte analyzer market?
- 9.Who are the key players/companies in the global blood gas and electrolyte analyzer market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Blood Gas and Electrolyte Analyzer Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product Type
- 6.1 Analyzers
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Consumables
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Modality
- 7.1 Benchtop
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Portable
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Clinics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Ambulatory Surgical Centers
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Dalko Diagnostics
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 Erba Group (Transasia Bio-Medicals Ltd.)
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.4 Medica Corporation
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.5 Nova Biomedical Corporation
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.6 OPTI Medical Systems Inc. (IDEXX Laboratories)
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.7 Radiometer Medical ApS (Danaher Corporation)
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.8 Roche Holding AG
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.9 Siemens AG
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 WerfenLife S.A.
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
°ü·ÃÀÚ·á